Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
HERIZON
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
- NCT02795988 ↗
- Completed
- Imugene Limited
- Deep
We haven't built an HCP commentary report on HERIZON (IMU-131 in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HERIZON so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 22 | |
| Podcasts | 4 | |
| YouTube | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2 Open-Label Study With Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Gastrointestinal Neoplasms; Adenocarcinoma
- Interventions
- IMU-131; Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Arms
- Phase 1b · Experimental
- Phase 2 - IMU 131 plus chemotherapy · Experimental
- Phase 2 - Chemotherapy only · Experimental
- Enrollment
- 64
- Primary outcomes
- Phase 1b: Number of Participants With Adverse Events (AEs)
- Phase 2: Overall Survival (OS)
- Phase 2 Extension: Number of Participants With AEs
- Sponsor
- Imugene Limited
- Start
- Aug 30, 2017
- Primary completion
- Mar 20, 2024
- Results posted
- Yes
- Registry record
- NCT02795988 · updated Apr 16, 2025
Publications
linked from the registry- Tobias J, Maglakelidze M, Andric Z, Ryspayeva D, Bulat I, Nikolic I, Petrovic Z, Chawla T, Nagarkar R, Garner-Spitzer E, Zielinski CC, Chong LMO, Nixon B, Ede NJ, Yavrom S, Kundi M, Wiedermann U. Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON). Clin Cancer Res. 2024 Sep 13;30(18):4044-4054. doi: 10.1158/1078-0432.CCR-24-0742. PubMed 39028916
- Wiedermann U, Garner-Spitzer E, Chao Y, Maglakelidze M, Bulat I, Dechaphunkul A, Arpornwirat W, Charoentum C, Yen CJ, Yau TC, Tanasanvimon S, Maneechavakajorn J, Sookprasert A, Bai LY, Chou WC, Ungtrakul T, Drinic M, Tobias J, Zielinski CC, Chong L, Ede NJ, Marino MT, Good AJ. Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001. Clin Cancer Res. 2021 Jul 1;27(13):3649-3660. doi: 10.1158/1078-0432.CCR-20-3742. Epub 2021 Apr 20. PubMed 33879458